(Q38056764)

27 August 2017

title

The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis (English)

1 reference

chronic obstructive pulmonary disease

27 August 2017

main subject

1 reference

1 reference

Robert Wilson

1

1 reference

27 August 2017

Aislinn Macklin-Doherty

series ordinal

2

1 reference

27 August 2017

publication date

31 October 2012

1 reference

Expert Review of Respiratory Medicine

27 August 2017

published in

1 reference

27 August 2017

volume

6

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

481-492

1 reference

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

27 August 2017

cites work

1 reference

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

21 January 2018

1 reference

Costs of chronic bronchitis and COPD: a 1-year follow-up study

21 January 2018

1 reference

COPD exacerbations: the importance of a standard definition

21 January 2018

1 reference

The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis.

21 January 2018

1 reference

Prevention of exacerbations of COPD with pharmacotherapy.

21 January 2018

1 reference

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

Bacteria, antibiotics and COPD.

21 January 2018

1 reference

Chronic mucus hypersecretion in COPD and death from pulmonary infection

21 January 2018

1 reference

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

21 January 2018

1 reference

Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

Infectious etiology of acute exacerbations of chronic bronchitis

21 January 2018

1 reference

Infection in the pathogenesis and course of chronic obstructive pulmonary disease

21 January 2018

1 reference

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease

21 January 2018

1 reference

Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease

21 January 2018

1 reference

Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD.

21 January 2018

1 reference

Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis

21 January 2018

1 reference

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

21 January 2018

1 reference

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

21 January 2018

1 reference

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers.

21 January 2018

1 reference

Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.

21 January 2018

1 reference

Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials

21 January 2018

1 reference

Quinolones in 2005: an update.

21 January 2018

1 reference

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

21 January 2018

1 reference

Quinolone-mediated bacterial death.

21 January 2018

1 reference

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

21 January 2018

1 reference

Mutant selection window hypothesis updated.

21 January 2018

1 reference

Maintaining fluoroquinolone class efficacy: review of influencing factors

21 January 2018

1 reference

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

21 January 2018

1 reference

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae

21 January 2018

1 reference

Profile of moxifloxacin drug interactions

21 January 2018

1 reference

Quinolones: action and resistance updated

21 January 2018

1 reference

Evaluation of the clinical microbiology profile of moxifloxacin

21 January 2018

1 reference

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

21 January 2018

1 reference

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

21 January 2018

1 reference

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

21 January 2018

1 reference

Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.

21 January 2018

1 reference

Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval

21 January 2018

1 reference

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

21 January 2018

1 reference

Outcome Predictors in Bronchitis

21 January 2018

1 reference

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results

21 January 2018

1 reference

Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study

21 January 2018

1 reference

Antimicrobial safety: focus on fluoroquinolones

21 January 2018

1 reference

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies

21 January 2018

1 reference

Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials

21 January 2018

1 reference

Arrhythmias associated with fluoroquinolone therapy

21 January 2018

1 reference

Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes

21 January 2018

1 reference

Guidelines for the management of adult lower respiratory tract infections--full version

21 January 2018

1 reference

Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD

21 January 2018

1 reference

Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare

21 January 2018

1 reference

Speed of Recovery from Acute Exacerbations of Chronic Obstructive Pulmonary Disease after Treatment with Antimicrobials

21 January 2018

1 reference

Effect of Various Antimicrobial Regimens on the Clinical Course of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Primary Care

21 January 2018

1 reference

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

21 January 2018

1 reference

Antibiotics for exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD004403.PUB2

Identifiers

DOI

10.1586/ERS.12.50

1 reference

27 August 2017

1 reference